drugset / Trial / NCT02964455
Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The phase I study is to determine the maximum tolerated dose and dose limiting toxicity of docetaxel and nedaplatin prescribed twice weekly in combination with concurrent chest radiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Timeline
- Start
- 2016-11
- Primary completion
- 2019-12
- Completion
- 2020-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 5 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 10 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 15 mg/m2 | Intravenous |
| Subject | Nedaplatin | Small molecule | 5 mg/m2 | Intravenous |
| Subject | Nedaplatin | Small molecule | 10 mg/m2 | Intravenous |
| Subject | Nedaplatin | Small molecule | 15 mg/m2 | Intravenous |